Search clinical trials for: RPT193

Total 26 results

RAPT Therapeutics, Inc.

Suspended

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Asthma

United States, Bulgaria, Czechia, Poland
RAPT Therapeutics, Inc.

Completed

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Atopic Dermatitis

United States, Netherlands
RAPT Therapeutics, Inc.

Suspended

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
RAPT Therapeutics, Inc.

Completed

Study of RPT193 in Healthy Adult Male Subjects

Healthy Male Subjects

United States
Azora Therapeutics Australia Pty Ltd

Active, not recruiting

Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis

Australia
Azora Therapeutics Australia Pty Ltd

Completed

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Australia
University Hospital, Angers

Unknown

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Huntington's Disease

France
EuroVacc Foundation
Medical Research Council; Centre Hospitalier Universitaire Vaudois; MRC/UVRI... and other collaborators

Completed

Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS (EV06)

HIV/AIDS

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

HIV Infections

United States
EuroVacc Foundation
Centre Hospitalier Universitaire Vaudois; MRC/UVRI and LSHTM Uganda Research... and other collaborators

Completed

Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial

HIV/AIDS

Uganda
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
Phanes Therapeutics

Recruiting

Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

Non Small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

United States
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
National Institute of Allergy and Infectious Diseases...
IPPOX Foundation; EuroVacc Foundation; Global Solutions for Infectious Diseases

Withdrawn

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

HIV Infections
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
MRC/UVRI and LSHTM Uganda Research Unit
King's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaborators

Enrolling by invitation

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

HIV Infections

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; EuroVacc Foundation; Global Solutions...

Withdrawn

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

HIV Infections
ANRS, Emerging Infectious Diseases
University College London Hospitals; Imperial College London; Medical Research... and other collaborators

Active, not recruiting

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Healthy Adults

United Kingdom, Switzerland, France
HIV Vaccine Trials Network

Completed

Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults

HIV Infections

Switzerland

Search clinical trials for: RPT193

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations